Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First Human Dose of Zalfermin in Overweight or Obese Men
NCT03015207Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2017
- Primary completion
- Oct 2017
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing Zalfermin with Placebo (2 arms). Primary endpoint: Number of treatment-emergent adverse events. Started Jan 2017; status: completed.
02
Drugs
nn9500
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03015207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015207.